These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 12398968

  • 1. Lessons learned from the valsartan- heart failure trial (Val-HeFT): angiotensin receptor blockers in heart failure.
    Cohn JN.
    Am J Cardiol; 2002 Nov 01; 90(9):992-3. PubMed ID: 12398968
    [No Abstract] [Full Text] [Related]

  • 2. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    Hollenberg NK.
    Curr Hypertens Rep; 2002 Dec 01; 4(6):411; discussion 412. PubMed ID: 12462208
    [No Abstract] [Full Text] [Related]

  • 3. Are angiotensin II receptor antagonists indicated in chronic heart failure?
    Komajda M.
    Heart Fail Monit; 2002 Dec 01; 2(3):85-7. PubMed ID: 12634889
    [Abstract] [Full Text] [Related]

  • 4. Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT Investigators.
    Cohn JN, Tognoni G, Glazer R, Spormann D.
    Eur J Heart Fail; 2000 Dec 01; 2(4):439-46. PubMed ID: 11113722
    [Abstract] [Full Text] [Related]

  • 5. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.
    Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN, Val-HeFT Investigators (Valsartan Heart Failure Trial).
    J Am Coll Cardiol; 2002 Oct 16; 40(8):1414-21. PubMed ID: 12392830
    [Abstract] [Full Text] [Related]

  • 6. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).
    Latini R, Masson S, Anand I, Judd D, Maggioni AP, Chiang YT, Bevilacqua M, Salio M, Cardano P, Dunselman PH, Holwerda NJ, Tognoni G, Cohn JN, Valsartan Heart Failure Trial Investigators.
    Circulation; 2002 Nov 05; 106(19):2454-8. PubMed ID: 12417542
    [Abstract] [Full Text] [Related]

  • 7. Val-HeFT: do angiotensin-receptor blockers benefit heart failure patients already receiving ACE inhibitor therapy?
    McMurray JJ.
    Nat Clin Pract Cardiovasc Med; 2005 Mar 05; 2(3):128-9. PubMed ID: 16265452
    [No Abstract] [Full Text] [Related]

  • 8. The benefits of valsartan in the treatment of heart failure: results from Val-HeFT.
    Tan LB, Schlosshan D, Williams SG.
    Int J Clin Pract; 2004 Feb 05; 58(2):184-91. PubMed ID: 15055867
    [Abstract] [Full Text] [Related]

  • 9. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT.
    Krum H, Carson P, Farsang C, Maggioni AP, Glazer RD, Aknay N, Chiang YT, Cohn JN.
    Eur J Heart Fail; 2004 Dec 05; 6(7):937-45. PubMed ID: 15556056
    [Abstract] [Full Text] [Related]

  • 10. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    Tepper D.
    Congest Heart Fail; 2002 Dec 05; 8(1):57-8. PubMed ID: 11821630
    [No Abstract] [Full Text] [Related]

  • 11. Valsartan in chronic heart failure.
    Haddy FJ.
    N Engl J Med; 2002 Apr 11; 346(15):1173-4. PubMed ID: 11948282
    [No Abstract] [Full Text] [Related]

  • 12. Angiotensin II type 1 receptor blockers and congestive heart failure.
    Auer JW, Berent R, Eber B.
    Circulation; 2001 Oct 09; 104(15):E82. PubMed ID: 11591633
    [No Abstract] [Full Text] [Related]

  • 13. [Angiotensin I receptor blockers for heart failure].
    Fruhwald FM, Kickenweiz E, Zweiker R, Klein W.
    Wien Med Wochenschr; 2001 Oct 09; 151(7-8):157-9. PubMed ID: 11450163
    [Abstract] [Full Text] [Related]

  • 14. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Reed SD, Friedman JY, Velazquez EJ, Gnanasakthy A, Califf RM, Schulman KA.
    Am Heart J; 2004 Jul 09; 148(1):122-8. PubMed ID: 15215801
    [Abstract] [Full Text] [Related]

  • 15. Improving outcomes in congestive heart failure: Val-HeFT. Valsartan in Heart Failure Trial.
    Cohn JN.
    Cardiology; 1999 Jul 09; 91 Suppl 1():19-22. PubMed ID: 10449891
    [Abstract] [Full Text] [Related]

  • 16. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.
    Wong M, Staszewsky L, Latini R, Barlera S, Volpi A, Chiang YT, Benza RL, Gottlieb SO, Kleemann TD, Rosconi F, Vandervoort PM, Cohn JN, Val-HeFT Heart Failure Trial Investigators.
    J Am Coll Cardiol; 2002 Sep 04; 40(5):970-5. PubMed ID: 12225725
    [Abstract] [Full Text] [Related]

  • 17. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
    Jorde UP, Ennezat PV, Lisker J, Suryadevara V, Infeld J, Cukon S, Hammer A, Sonnenblick EH, Le Jemtel TH.
    Circulation; 2000 Feb 29; 101(8):844-6. PubMed ID: 10694521
    [Abstract] [Full Text] [Related]

  • 18. Effect of Valsartan on hospitalization: results from Val-HeFT.
    Carson P, Tognoni G, Cohn JN.
    J Card Fail; 2003 Jun 29; 9(3):164-71. PubMed ID: 12815565
    [Abstract] [Full Text] [Related]

  • 19. Implications of recent clinical trials for heart failure performance measures.
    Executive Council Of The Heart Failure Society Of AmericaHeart Failure Society Of America, Court International Suite 240 South, 2550 University Avenue West, St. Paul, MN 55114, USA..
    J Card Fail; 2004 Feb 29; 10(1):4-5. PubMed ID: 14966767
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.